Strategic Partnerships Leverage OBT's extensive collaboration history with Boehringer Ingelheim, Roche, and Bristol Myers Squibb to position your company for co-development or licensing discussions, highlighting validation from top-tier pharma and access to OGAP platform capabilities.

Platform leverage OEM potential buyers can explore opportunities to license or co-develop OGAP Verify for target discovery and validation in oncology, emphasizing access to one of the largest proprietary cancer membrane proteomic databases and accelerating target-to-clinic timelines.

Clinical pipeline Target entities seeking late-stage IO and ADC opportunities should consider OBT076 and related programs for partnering in Phase 1b to Phase 3 progression, presenting a pathway to expand their immuno-oncology portfolios with first-in-class modalities.

Market expansion Capitalize on multi-market exposure across the US and Europe by offering regional development or manufacturing partnerships, aligning with OBT’s global clinical development footprint and existing international collaborations.

Funding & growth Propose financing or strategic alliances tied to scale-up, manufacturing capacity, and commercialization planning, leveraging OBT’s revenue range and growth trajectory to attract investors or strategic buyers seeking oncology innovation.